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Abstract
Background: Health-related quality of life (HRQoL) has been positioned as one of the major endpoints in oncology.
Thus, there is a need to validate cancer-site specific survey instruments. This study aimed to perform a transcultural
adaptation of the 50-item Expanded Prostate cancer Index Composite (EPIC) questionnaire for HRQoL in prostate
cancer patients and to validate the psychometric properties of the French-language version.
Methods: The EPIC questionnaire measures urinary, bowel, sexual and hormonal domains. The first step,
corresponding to transcultural adaptation of the original English version of the EPIC was performed according to
the back translation technique. The second step, comprising the validation of the psychometric properties of the
EPIC questionnaire, was performed in patients under treatment for localized prostate cancer (treatment group) and
in patients cured of prostate cancer (cured group). The EORTC QLQ-C30 and QLQ-PR25 prostate cancer module
were also completed by patients to assess criterion validity. Two assessments were performed, i.e., before and at
the end of treatment for the Treatment group, to assess sensitivity to change; and at 2 weeks’ interval in the Cured
group to assess test-retest reliability. Psychometric properties were explored according to classical test theory.
Results: The first step showed overall good acceptability and understanding of the questionnaire. In the second
step, 215 patients were included from January 2012 to June 2014: 125 in the Treatment group, and 90 in the Cured
group. All domains exhibited good internal consistency, except the bowel domain (Cronbach’s α = 0.61). No floor
effect was observed. Test-retest reliability assessed in the cured group was acceptable, expect for bowel function
(intraclass coefficient = 0.68). Criterion validity was good for each domain and subscale. Construct validity was not
demonstrated for the hormonal and bowel domains. Sensitivity to change was exhibited for 5/8 subscales and 2/4
summary scores for patients who experienced toxicities during treatment.
Conclusions: The French EPIC questionnaire seems to have adequate psychometric properties, comparable to
those exhibited by the original English-language version, except for the construct validity, which was not available
in original version.
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Background
Prostate cancer is the second most common cause of can-
cer and the sixth leading cause of cancer death among
men worldwide, with an estimated 1.1 million cases in
2012 and 307,000 new deaths [1]. In France, prostate
cancer has been the most frequent cancer in men for the
last two decades, with around 54,000 new prostate cancers
diagnosed in 2011 [2]. However, prostate cancer is the
fifth overall cause of cancer-related death, with less than
10,000 deaths per year as of 2011 [2].
For prostate cancer that is diagnosed when still at a local
stage, several curative treatment strategies exist that can
achieve long-term remission. However, these treatments
can induce significant functional impairment at the
urinary, sexual, digestive and hormonal level [3, 4]. In this
context, health-related quality of life (HRQoL) is an im-
portant endpoint for such patients. Moreover, HRQoL is
now recognized as a second primary endpoint by the
American Society of Clinical Oncology and the Food and
Drug Administration if no effect of treatment on overall
survival is observed [5–7].
In order to capture all symptoms specific to prostate
cancer and the side effects of prostate cancer treatment,
it is recommended to use disease-specific HRQoL
questionnaires [8]. These questionnaires must also be
adapted to the culture and the language of the study [9],
especially in non-English-speaking countries, and
validation of the psychometric properties of adapted
questionnaires remains mandatory.
Few HRQoL questionnaires specific to prostate cancer
have been validated in the French language. The QLQ-
PR25 prostate-cancer-specific module of the European
Organization of Research and Treatment of Cancer
(EORTC) is available and validated in French [10], but
only explores symptoms from a factual point of view.
The University of California-Los Angeles Prostate Can-
cer Index (UCLA-PCI) is widely used in English-
speaking countries [11]. The Expanded Prostate Cancer
Index Composite (EPIC) was developed from the
UCLA-PCI by supplementing it with items focusing on
urinary irritative and obstructive voiding symptoms and
with items addressing hormonal symptoms [12]. The
availability of a validated French-language version of the
EPIC, which would be better adapted to epidemiological
studies [13], is thus essential to allow comparison of
French data with existing reports in the international
literature.
In this context, the objective of this study was to per-
form transcultural adaptation and validation of the
French version of the EPIC questionnaire according to
classical test theory. This study is part of the French
National QALIPRO project that aims to investigate the
long-term side effects of prostate cancer, in which the
EPIC questionnaire is used.
Methods
Study design
The validation of the French version of the EPIC question-
naire was performed in two steps. Nine French cancer care
centers and university hospitals participated in patient
recruitment.
Step 1: Transcultural adaptation and qualitative validation
(face validity)
Transcultural adaptation of the EPIC questionnaire in
French was done using back translation technique and
was pretested on a planned sample of 50 patients [14].
These patients were recruited during urology or radiother-
apy consultations. Patients had to fill out a debriefing
questionnaire to assess their completion of the EPIC: i.e.,
they could indicate if the questionnaire was too long, or
too complicated, or if some items were found to be dis-
turbing, irrelevant, redundant or missing, among other
questions. The time required to complete the question-
naire was also recorded. This information gave an indica-
tion of both the quality of the translation and the possible
acceptability of the questionnaire.
Step2: Quantitative validation of the psychometric
properties of the questionnaire
Participants For the second step, both patients with on-
going treatment and cured patients were recruited and
categorized into two groups as follows:
– In the Cured group, patients had to be considered
cured of prostate cancer (≥3 years after diagnosis),
regardless of initial treatment, and attending a follow-up
consultation. Patients with recurrence were excluded.
– In the Treatment group, patients were prospectively
included before curative treatment for localized
prostate cancer. Patients were eligible to participate
if they had a histologically confirmed diagnosis of
localized prostate cancer, and if they had no
previous treatment for their prostate cancer. Patients
were excluded if the curative treatment had already
been performed, or in case of metastasis.
All patients had to have social security coverage, and
had to be able to complete HRQoL questionnaires. All
patients were fully informed of the study and provided
signed written informed consent. The protocol was
approved by the local ethics committee (Comité de
Protection des Personnes Est II).
Questionnaires Patients were required to complete the
EPIC questionnaire, as well as the EORTC QLQ-C30
cancer specific questionnaire, and the QLQ-PR25 pros-
tate cancer module, to assess criterion validity.
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The EPIC questionnaire is a 50-item instrument spe-
cific to prostate cancer developed and validated in the
English language [12]. Items are separated in domains
and each item contains four or five response categories.
The questionnaire assesses four domains, namely:
urinary, bowel, sexual and hormonal; and each domain
comprises two subscales, namely symptom severity
(function subscale) and symptom-related impairment
(bother subscale). The urinary domain can also be sepa-
rated into two other subscales, combining both function
and bother items, namely a urinary incontinence
subscale and a urinary irritation/obstruction subscale.
The last item evaluates overall satisfaction. Scale scores
(one score per subscale) are transformed linearly to a 0-
to-100 scale, with higher scores representing higher
HRQOL, i.e., high function and low bother. A summary
score is also generated for each domain, corresponding
to the mean of the function and bother subscales. Scores
were generated according to the recommendations of
the questionnaire developers [15].
The QLQ-C30 includes 30 items and measures five
functional scales (physical, role, emotional, cognitive and
social functioning), global health status (GHS), financial
difficulties and eight symptom scales (fatigue, nausea
and vomiting, pain, dyspnea, insomnia, appetite loss,
constipation, diarrhea) [16]. One score is generated for
each dimension. Scores vary from 0 (worst) to 100 (best)
for the functional dimensions and GHS, and from 0
(best) to 100 (worst) for the symptom dimensions, and
were generated according to the EORTC Scoring
Manual [17].
The QLQ-PR25 module contains 25 items assessing
two functional scales (sexual activity and sexual
functioning) and four symptomatic scales (urinary
symptoms, bowel symptoms, hormone treatment-
related symptoms and incontinence aid) specific to
prostate cancer. This module must be completed in
conjunction with the QLQ-C30 questionnaire. As with
the QLQ-C30, one score is generated for each scale
and standardized on a 0–100 scale such that a high
score represents a high functional or symptomatic
level [10].
Measurement times Patients were required to complete
the questionnaires twice, as follows:
– In the Cured group, patients completed the
questionnaires at baseline (T1) and again 2 weeks
later (T2) to assess test-retest reliability;
– In the Treatment group, patients completed the
questionnaires immediately before the initiation of
treatment (T1) and then again at the end of
treatment (6 to 8 weeks after the first assessment,
T2) to assess sensitivity to change.
Sample size calculation
For the qualitative validation, we planned to include 50
patients.
For the quantitative validation of the psychometric
properties of the EPIC questionnaire, it was planned to
include 300 patients in order to ensure the statistical ro-
bustness of the analyses. In particular, exploratory factor
analysis (EFA) to investigate the dimensionality of the
questionnaire requires a minimum of 150 patients [18],
with a minimum of 30 patients per response category
with 5 response categories per item. We planned to in-
clude 100 patients in the Cured group and 200 patients
in the Treatment group.
In the Treatment group, to highlight a minimal clinic-
ally important difference (MCID) of 10 points in one di-
mension between both questionnaire measurements,
with a standard deviation (SD) of 20 points, a type I
error of 5% and statistical power of 80%, a minimum of
150 patients was required (75 patients in two groups de-
fined by an external criteria).
Statistical analysis
Baseline socio-demographic and clinical characteristics
of the patients are described using mean ± SD or median
(range) for continuous variables, and number (percent-
age) for qualitative variables.
Face validity was assessed using the debriefing ques-
tionnaire from step 1.
All other analyses were performed on the validation
population from step 2 including all patients (both
Cured and Treatment groups) at the first measurement
point (except if a specific population is concerned).
Acceptability of the questionnaire was assessed by the
percentage of missing data (missing items and missing
forms). A high proportion of missing forms may indicate
poor acceptability of the instrument [8]. Information
provided in the debriefing questionnaire in step 1 was
also used to gain additional insights into the acceptabil-
ity of the questionnaire. For example, if the patient
found some questions to be disturbing, difficult to
understand, or found the questionnaire too long, this
could explain some missing data and could similarly lead
to missing data in future studies. The debriefing ques-
tionnaire was summarized as number and percentage for
each question for all patients of step 1. The mean ± SD
time required to complete the questionnaire was also
reported.
Floor and ceiling effects were estimated for each sub-
scale and for the overall score. The number and percent-
age of patients who obtained the lowest or highest
possible score for each subscale and overall domain were
recorded. Floor or ceiling effects were considered to be
present if more than 15% of the responders achieved the
lowest or highest possible score respectively [19].
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Reliability of the questionnaire was assessed using
Cronbach’s α coefficient for internal consistency and the
test-retest method for repeatability. Cronbach’s α was
estimated for all subscales and overall domains. It was
expected to be higher than 0.70 [20]. Test-retest reliabil-
ity was assessed from the data of the Cured group with
estimation of the interclass correlation coefficient (ICC)
between assessments T1 and T2 [21].
Convergent and discriminant validities were evaluated
using multitrait scaling analysis [18] conducted separ-
ately for the eight subscales and for the four domains.
The convergent validity of each item was assessed using
Spearman’s correlation coefficient between each item
and its own subscale score, computed without including
the corresponding item. The convergent validity was
considered satisfactory if the correlation coefficient was
higher than 0.40, in absolute value. For the discriminant
validity, the correlation between each item and its own
scale score was expected to be greater than the correl-
ation between that item and the other scale scores. Simi-
lar analyses were conducted for each domain.
EFA was performed to assess the dimensionality of the
questionnaire with orthogonal rotation of the factors
and imposing four factors. All items were integrated into
the EFA except the last item assessing overall satisfac-
tion. EFA was performed on patients who had completed
all items at the first measurement timepoint. The vari-
ance explained by the four factors was reported and the
resulting factors were interpreted [22].
Criterion validity was assessed using a correlation
matrix between the EPIC domain summary scores and the
QLQ-PR25 scores. The correlation between the EPIC and
QLQ-PR25 scores assessing the same HRQoL domain
was expected to be higher than 0.4, in absolute value.
Conversely, the correlation between each EPIC domain
summary score and other scales of the QLQ-PR25 asses-
sing other HRQoL domains was expected to be lower.
Sensitivity to change was assessed among patients
from the Treatment group by comparing, using a paired
T-test, the change in scores between T2 and T1 accord-
ing to the presence or absence of at least one toxicity
rated grade 2 or higher during treatment. We assumed
that patients experiencing at least one toxicity would ex-
perience a greater deterioration in their HRQoL level
than patients without toxicity. Mean change between T2
and T1, with the SD of the change between the two
measures was reported. The Standardized Response
Mean (SRM) was also estimated, corresponding to the
mean change divided by the SD of change. An absolute
SRM value less than 0.2 was considered as a “small”
change, between 0.2 and 0.5 as “moderate”, and greater
than 0.5 as “large” [23]. Each domain and subscale was
analysed without any specific hypothesis as to whether
the effect of toxicity on each scale was similar. The
median (range) time between the two assessments was
also reported. We expected a clinically significant change
of at least 10 points in all the subscales and summary
scores for patients who experienced toxicities during
treatment.
All analyses were performed using SAS version 9.4
(SAS Institute Inc., Cary, NC, USA). All tests were two-
sided and the type I error was set at 0.05. No adjustment
for multiple testing was performed.
Results
Step1: Face validity
Forty-six patients were included in step 1. None of them
considered the questionnaire to be too long. Five
patients (11.6%) reported that they found at least one
question disturbing. These patients mainly reported that
the disturbing questions referred to symptoms that they
did not experience, so they had some difficulty judging
the impact of the given symptom on their HRQoL level,
for example. Two patients mentioned that they found
some questions to be disturbing, explaining that it was
too private (questions 17 and 21 about sexuality). Four
patients (8.7%) needed help completing the question-
naire. Twenty-eight patients (62.2%) considered that the
questionnaire addressed relevant issues. Forty-one pa-
tients (91.1%) considered that the questionnaire might
concern other men. Finally, 38 patients (84.4%) declared
that the questionnaire enabled them to deal more easily
with problems or difficulties related to their disease. The
mean time required to complete the questionnaire was
less than 20 min (mean 19.8, SD = 9.3). In light of these
results, the French version of the EPIC questionnaire
tested in step 1 was maintained as is for step 2.
Step2: Quantitative validation of psychometric properties
Study population
In step 2, 215 patients were included between January
2012 and June 2014: 125 patients in the Treatment
group and 90 patients in the Cured group. The mean
age was 68 years (SD = 6.6). The baseline socio-
demographic and clinical characteristics of the study
population are summarized in Table 1.
Validation of the psychometric properties
Acceptability Nineteen patients (8.8%) did not fill out
the baseline EPIC questionnaire: 11 patients (8.8%) in
the Treatment group and 8 patients (8.8%) in the Cured
group. Nine of these patients (47.4%) reported that they
forgot to return the questionnaire. Eighty-one patients
(37.7%) fully completed the baseline questionnaire.
Floor and ceiling effects Mean (SD) scores for all pa-
tients at baseline, as well as the percentage of lowest or
highest possible scores to quantify floor and ceiling
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effects respectively, for each subscale and for each sum-
mary score are given in Table 2. A ceiling effect (i.e.,
more than 15% of patients having the highest possible
score) was observed for the bowel (15.35%) and hormo-
nal (20.93%) summary scores, and for the main sub-
scales, except for the sexual subscales, bother, and the
irritation/obstruction subscales of the urinary domain.
No floor effect was observed.
Reliability Regarding internal consistency, Cronbach’s
alpha was ≥ 0.70 for each subscale except for urinary func-
tion, bowel function and hormonal symptoms, where Cron-
bach’s alpha was 0.63, 0.53 and 0.63 respectively (Table 2).
Regarding the summary scores, Cronbach’s alpha coefficient
was <0.70 for the bowel domain only (0.61).
Table 3 displays the mean (SD) scores for each sum-
mary score and subscale for patients in the Cured group
at the two measurement times, as well as the ICC for
test-retest reliability. An ICC ≥ 0.70 was observed for
each subscale and summary score, except for bowel
function, where the ICC was 0.68.
Construct validity Convergent validity was achieved for
all items of the sexual function subscale, with a correl-
ation between the sexual function score and summary
score greater than 0.4 (Table 4). Regarding the items of
the sexual bother subscale, the convergent validity was
respected in terms of correlation with the sexual bother
score, but not for the sexual domain summary score,
with the correlation between each item and the sum-
mary score being less than 0.4. Convergent validity was
also respected for all items of the urinary bother sub-
scale, except for item q30, with a correlation of −0.28
with both the urinary bother subscale score and the
urinary domain summary score. Likewise, convergent
validity was also respected for all items of the bowel
bother subscale, except for item q53, with a correlation
of −0.38 with the bowel bother subscale score, and −0.31
with bowel domain summary score. For all other dimen-
sions, the convergent validity was respected for only a
minority of items, in particular hormonal function,
where no item of this subscale respected the convergent
validity with respect to its own subscale. Yet, most of
items of the hormonal scale respected the convergent
validity with the overall hormonal domain.
Discriminant validity was achieved for all items of
both the urinary and sexual domains. Conversely,
Table 1 Baseline characteristics of the patients
All patients Cured group Treatment group
N = 215 N = 90 N = 125
N % N % N %
Age. mean (SD) 187 68.1 (6.6) 76 70.0 (6.5) 111 66.9 (6.3)
Marital status
Living maritally 162 75.3 70 77.8 92 73.6
Divorced 17 7.9 6 6.7 11 8.8
Widower 6 2.8 3 3.3 3 2.4
Single 6 2.8 1 1.1 5 4.0
Missing data 24 11.1 10 11.1 14 11.2
Profession
Retired 158 73.5 75 83.3 83 66.4
Professionally active 29 13.5 5 5.6 24 19.2
Unemployed 2 0.9 0 0 2 1.6
Missing data 26 12.1 10 11.1 16 12.8
Performance Status at baseline
0 192 89.3 81 90 111 88.8
1 13 6.0 4 4.4 9 7.2
2 2 0.9 1 1.1 1 0.8
3 0 0 0 0 0 0
4 0 0 0 0 0 0
Missing data 8 3.7 4 4.4 4 3.2
Cancer stage at diagnosis
Local 205 95.3 84 93.3 121 96.8
Locoregional 6 2.8 2 2.2 4 3.2
Metastatic 0 0 0 0 0 0
Missing data 4 1.9 4 4.4 0 0
Disease treatment
Chemotherapy
Yes 0 0 0 0 0
No 208 96.7 86 95.6 122 97.6
Missing data 7 3.3 4 4.4 3 2.4
Radiotherapy
Yes 112 52.1 58 64.4 54 43.2
No 97 45.1 27 21.4 70 56
Missing data 6 2.8 5 5.6 1 0.8
Hormone therapy
Yes 45 20.9 22 17.5 23 18.4
No 162 75.3 64 71.1 98 78.4
Missing data 8 3.7 4 4.4 4 3.2
Surgery
Yes 103 47.9 44 48.9 59 47.2
No 103 47.9 41 45.5 62 49.6
Missing data 9 4.2 5 5.6 4 3.2
Table 1 Baseline characteristics of the patients (Continued)
Brachytherapy
Yes 17 7.9 13 14.4 4 3.2
No 187 87.0 73 81.1 114 91.2
Missing data 11 5.1 4 4.4 7 5.6
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discriminant validity was not respected for 5/7 items of
the bowel function subscale, 1/7 item of the bowel
bother subscale, 3/5 items of the hormonal function sub-
scale and 2/6 items of the hormonal bother subscale.
The result of the EFA is summarized in Table 5.
Fifty-three percent of the variance was explained by
the four factors. Items of the sexual function subscale
were highly correlated with Factor 1, while those of
the sexual bother subscale were correlated with Factor
2. Most of the items of the urinary domain were
correlated with Factor 3 while those of the bowel do-
main were correlated with Factor 4. Finally, items of
the hormonal domain were equally distributed over
the first three factors.
Criterion validity Correlation between each EPIC sum-
mary score and the equivalent scale of the QLQ-PR25
was greater than 0.4, highlighting good criterion validity
(Table 6). In particular, the correlation was highest be-
tween the urinary symptoms scale of the QLQ-PR25
module and the urinary summary score of the EPIC
questionnaire, at −0.83. The urinary, sexual and hormo-
nal summary scores of the EPIC were also highly corre-
lated with the incontinence aid dimension of the QLQ-
PR25 (at −0.66, −0.55 and −0.57, respectively).
Sensitivity to change The median time between the
two assessments was 7.8 weeks (range 3.2–12.8). Among
the patients of the Treatment group, 55 (44%) experi-
enced at least one toxicity rated grade 2 or higher during
treatment. For all subscales and summary scores, these
patients experienced a decrease of mean HRQoL at T2
as compared to T1, with a clinically significant difference
(10-point MCID) observed for 7/10 subscales and 2/4
summary scores (Table 7). As compared to patients
without toxicity during treatment, patients who experienced
toxicities presented a greater decrease in the sexual sum-
mary score (mean difference =−30.59 vs. -13.61, P-value <
0.001), urinary function subscale (mean difference =−31.57
vs. -18.48, P-value = 0.004), incontinence subscale (mean dif-
ference = −45.67 vs. -18.13, P-value < 0.001), sexual function
subscale (mean difference =−38.68 vs. -21.80, P-value =
0.001) and sexual bother subscale (mean difference = −14.10
vs. 1.83, P-value = 0.022).
Discussion
This paper reports the cross-cultural adaptation and val-
idation of the French version of the EPIC HRQoL ques-
tionnaire specific to prostate cancer, using classical test
theory. The qualitative step overall exhibited good ac-
ceptability and understanding of the questionnaire. Few
Table 2 Characteristics of EPIC domain-specific summary and subscales scores (N = 215; T1)






Cronbach’s α Cronbach’s α in the original
version (Wei et al. 2000)
HRQoL Domain Summary Scores
Urinary 12 167 86.74 (13.61) 33.33–100 0 9.30 0.88 0.88
Bowel 14 165 91.70 (9.93) 30.36–100 0 15.35 0.61 0.92
Sexual 13 177 43.88 (21.98) 0.0–94.23 0.93 0 0.89 0.93
Hormonal 11 162 87.67 (12.49) 47.50–100 0 20.93 0.77 0.82
Domain-Specific HRQoL Subscales
Urinary subscales
Function 5 192 94.39 (11.02) 40.00–100 0 60.47 0.63 0.69
Bother 7 162 82.03 (17.33) 17.86–100 0 10.70 0.85 0.85
Irritation/obstruction 7 163 85.42 (14.42) 17.86–100 0 11.16 0.79 0.81
Incontinence 4 167 91.44 (17.22) 22.75–100 0 53.93 0.91 0.89
Bowel subscales
Function 7 190 92.46 (9.07) 39.29–100 0 23.72 0.53 0.75
Bother 7 165 90.72 (13.36) 21.43–100 0 30.70 0.83 0.90
Sexual subscales
Function 9 174 40.76 (28.96) 0.00–91.67 8.84 0 0.96 0.92
Bother 4 166 53.61 (34.14) 0.00–100 7.91 14.88 0.94 0.84
Hormonal subscales
Function 5 186 86.99 (13.18) 25.00–100 0 26.51 0.76 0.51
Bother 6 163 88.32 (13.59) 45.83–100 0 25.58 0.63 0.73
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patients reported that they found the questions to be
disturbing, and the comments provided showed that this
was not due to translation problems, but rather to the
construction of the questionnaire itself, since some
symptoms were not experienced by the patients and
therefore, they found it difficult to judge its impact,
while some other items were perceived to be too private.
The number of patients who refused to participate in
this study could also be informative for acceptability, but
unfortunately, it was not possible to collect this data in
each center.
Ceiling effects were found for bowel and urinary sum-
mary scores, although the percentage of patients with
the highest possible score was close to the threshold of
15% for the urinary domain. A high ceiling effect was
observed for the function and incontinence subscales of
the urinary domain. Conversely, no floor effect was ob-
served for any domain or subscale. Similar findings were
observed in the original English version of the EPIC
questionnaire [12].
Good internal consistency was observed for all sum-
mary scores, except for the bowel domain, where the
Cronbach’s alpha was 0.61. The repeatability was also
demonstrated for all domains and subscales, expect for
bowel function (ICC = 0.68). Thus, the reliability of the
questionnaire was globally good for all scales, except for
the bowel dimension. In comparison, good internal
consistency and repeatability were observed for each
subscale, except for hormonal function (Cronbach’s
alpha coefficient 0.51), and for all summary scores in the
original English version [12].
We also observed high criterion validity, with a high
correlation between EPIC domains and the equivalent
scales of the QLQ-PR25. Wei et al. [12] compared the
English version of the EPIC questionnaire to both the
Functional Assessment of Cancer Therapy-Prostate
(FACT-P) module [24] and to the American Urological
Association Symptom Index (AUA-SI) [25, 26]. For both
these prostate-cancer-specific questionnaires, only one
overall score is generated. The QLQ-PR25 presents the
advantage, as with the EPIC, of generating scores for
each HRQoL domain, and may thus be considered to be
more precise.
The sensitivity to change assessed in this study
highlighted a clinically and statistically significant change
on 5 of the 8 subscales, and 2 of the 4 summary scores
in patients who experienced toxicity during treatment.
Compared to patients who did not suffer toxicity during
treatment, those with toxicities had a greater decrease in
the sexual summary score, and in the urinary and sexual
Table 3 Assessment of test-retest reliability between the two assessment times for the Cured group
Time 1: baseline Time 2: two weeks later
HRQoL domain N mean (SD) N mean (SD) ICC for test-retest
(ICC of Original version)
HRQoL domain summary scores
Urinary 71 84.31 (15.01) 64 86.19 (14.18) 0.90 (0.88)
Bowel 70 89.34 (11.79) 67 89.54 (12.64) 0.86 (0.84)
Sexual 72 33.18 (20.84) 73 33.67 (20.18) 0.94 (0.91)
Hormonal 70 86.70 (13.15) 67 88.53 (13.34) 0.89 (0.80)
Domain-specific HRQoL subscales
Urinary subscales
Function 80 90.73 (14.37) 76 91.80 (13.29) 0.84 (0.83)
Bother 68 80.42 (17.11) 63 82.36 (18.39) 0.90 (0.87)
Irritation/obstruction 68 85.31 (13.28) 63 86.43 (13.48) 0.82 (0.85)
Incontinence 72 85.10 (22.09) 65 87.88 (19.28) 0.94 (0.87)
Bowel subscales
Function 80 90.76 (10.46) 77 91.79 (9.94) 0.68 (0.78)
Bother 70 88.10 (15.14) 66 88.49 (16.26) 0.88 (0.85)
Sexual subscales
Function 71 26.06 (26.82) 74 25.07 (25.80) 0.98 (0.90)
Bother 68 53.03 (36.36) 69 51.90 (33.23) 0.78 (0.78)
Hormonal subscales
Function 78 85.40 (15.07) 76 88.49 (13.63) 0.76 (0.79)
Bother 70 87.50 (13.63) 65 89.91 (13.44) 0.84 (0.73)
SD standard deviation, ICC intraclass coefficient
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Table 4 Mutitrait matrix with correlation of each item and the domain-specific HRQoL subscales and summary scores
























Urinary Function q23 0.48 0.59 0.56 0.38 0.27 0.36 0.29 0.28 0.06 0.32 0.30 0.29
q24 0.15 −0.04 0.21 0.16 0.06 0.19 0.03 0.03 0.02 0.03 −0.03 0.08
q25 0.43 0.21 0.40 0.42 0.41 0.32 0.11 0.11 0.01 0.22 0.20 0.16
q26 0.58 0.63 0.50 0.43 0.32 0.39 0.32 0.33 0.02 0.27 0.31 0.21
q27 −0.50 −0.63 −0.40 −0.31 −0.30 −0.24 −0.26 −0.25 −0.07 −0.37 −0.40 −0.30
Bother q28 −0.60 −0.72 −0.45 −0.34 −0.30 −0.30 −0.29 −0.26 −0.10 −0.33 −0.33 −0.29
q29 −0.54 −0.46 −0.50 −0.48 −0.36 −0.46 −0.13 −0.08 −0.11 −0.32 −0.25 −0.30
q30 −0.28 −0.19 −0.28 −0.19 −0.01 −0.25 −0.03 −0.03 −0.03 −0.23 −0.14 −0.27
q31 −0.58 −0.35 −0.62 −0.46 −0.35 −0.45 −0.17 −0.12 −0.14 −0.32 −0.26 −0.32
q32 −0.59 −0.32 −0.65 −0.42 −0.32 −0.37 −0.25 −0.26 −0.07 −0.37 −0.32 −0.36
q33 0.56 −0.32 −0.60 −0.33 −0.27 −0.27 −0.26 −0.23 −0.13 −0.29 −0.21 −0.28
q34 −0.75 −0.52 −0.74 −0.43 0.31 −0.42 −0.27 −0.24 −0.11 −0.39 −0.36 −0.36
Bowel Function q42 0.23 0.23 0.22 0.28 0.24 0.27 0.16 0.16 0.02 0.13 0.20 0.12
q43 0.31 0.40 0.25 0.50 0.34 0.51 0.10 0.06 0.05 0.33 0.29 0.30
q44 −0.25 −0.14 −0.25 −0.32 −0.23 −0.32 −0.08 −0.10 0.03 −0.28 −0.20 −0.30
q45 −0.15 −0.13 −0.14 −0.17 −0.17 −0.18 −0.17 −0.19 0.02 −0.10 −0.11 −0.10
q46 −0.36 −0.34 −0.33 −0.48 −0.40 −0.45 −0.23 −0.20 −0.08 −0.30 −0.26 −0.29
q47 −0.11 −0.12 −0.11 −0.19 −0.17 −0.19 −0.09 −0.10 0.02 −0.06 −0.12 −0.02
q48 0.38 0.30 0.33 0.49 0.42 0.44 0.10 0.05 0.07 0.13 0.23 0.07
Bother q49 −0.42 −0.35 −0.39 −0.69 −0.51 −0.62 −0.27 −0.24 −0.08 −0.3 −0.22 −0.34
q50 −0.49 −0.44 −0.48 −0.67 −0.52 −0.64 −0.29 −0.24 −0.14 −0.36 −0.28 −0.37
q51 −0.30 −0.18 −0.34 −0.53 −0.36 −0.55 −0.16 −0.19 −0.15 −0.24 −0.15 −0.30
q52 −0.39 −0.39 −0.35 −0.56 −0.38 −0.60 −0.06 0.01 −0.09 −0.27 −0.19 −0.30
q53 −0.35 −0.27 −0.36 −0.31 −0.40 −0.38 −0.09 −0.02 −0.12 −0.24 −0.17 −0.28
q54 −0.35 −0.27 −0.36 −0.57 −0.40 −0.55 −0.09 −0.02 −0.12 −0.24 −0.17 −0.28
q55 −0.37 −0.32 −0.33 −0.61 −0.50 −0.58 −0.21 −0.13 −0.18 −0.36 −0.26 −0.37
Sexual Function q56 0.28 0.30 0.22 0.23 0.24 0.15 0.56 0.76 −0.23 0.14 0.22 0.10
q57 0.28 0.32 0.23 0.25 0.22 0.20 0.83 0.89 0.09 0.12 0.18 0.10
q58 0.30 0.29 0.26 0.22 0.22 0.17 0.72 0.86 −0.04 0.15 0.20 0.13
q59 0.33 0.37 0.27 0.25 0.22 0.20 0.71 0.83 −0.06 0.14 0.17 0.14
q60 0.29 0.32 0.24 0.24 0.19 0.17 0.76 0.85 0.02 0.09 0.11 0.08



















Table 4 Mutitrait matrix with correlation of each item and the domain-specific HRQoL subscales and summary scores (Continued)
q62 0.27 0.28 0.22 0.22 0.20 0.17 0.69 0.80 −0.04 0.11 0.16 0.09
q63 0.22 0.27 0.17 0.19 0.18 0.14 0.69 0.83 −0.07 0.06 0.11 0.05
q64 0.23 0.26 0.20 0.24 0.20 0.17 0.79 0.91 −0.02 0.07 0.11 0.05
Bother q65 −0.11 <0.01 −0.14 −0.12 −0.04 −0.16 −0.22 0.09 −0.90 −0.23 −0.09 −0.24
q66 −0.13 −0.04 −0.16 −0.13 −0.05 −0.16 −0.27 0.06 −0.91 −0.25 −0.14 −0.26
q67 −0.09 −0.05 −0.08 −0.08 <0.01 −0.14 −0.25 0.07 −0.88 −0.27 −0.13 −0.29
q68 −0.19 −0.07 −0.22 −0.16 −0.07 −0.18 −0.30 −0.04 −0.75 −0.23 −0.18 −0.20
Hormonal Function q69 0.16 0.16 0.16 0.13 0.20 0.05 0.22 0.28 −0.05 0.31 0.11 0.36
q70 0.23 0.12 0.22 0.01 0.19 0.01 −0.10 0.01 −0.05 0.15 0.22 0.09
q71 0.20 0.21 0.22 0.26 0.20 0.25 0.10 −0.02 0.24 0.46 0.23 0.53
q72 0.40 0.29 0.37 0.31 0.23 0.28 0.17 0.07 0.21 0.51 0.34 0.54
q73 −0.08 −0.04 −0.05 0.08 0.08 0.06 0.04 0.06 −0.06 0.03 0.08 −0.02
Bother q74 −0.19 −0.11 −0.19 −0.09 −0.12 −0.03 −0.20 −0.16 −0.15 −0.43 −0.48 −0.27
q75 −0.25 −0.09 −0.30 −0.10 −0.16 −0.09 0.03 0.05 <0.01 −0.11 −0.21 −0.05
q76 −0.17 −0.07 −0.20 −0.12 −0.08 −0.15 0.05 0.10 0.01 −0.17 −0.05 −0.25
q77 −0.30 −0.23 −0.28 −0.40 −0.26 −0.45 −0.10 0.02 −0.26 −0.58 −0.54 −0.54
q78 −0.40 −0.32 −0.37 −0.41 −0.30 −0.42 −0.21 −0.08 −0.31 −0.64 −0.58 −0.60
q79 −0.24 −0.16 −0.28 −0.23 −0.15 −0.23 −0.17 −0.10 −0.18 −0.33 −0.40 −0.23
Values in bold for item own-scale correlation and item own-domain correlation correspond to items respecting convergent validity, i.e., correlation >0.4 in absolute value. Values in bold for correlation between an item



















subscales. Wei et al. did not assess the sensitivity to
change of the original English version of the EPIC,
therefore precluding comparison with our results [12].
Regarding the construct validity, multitrait analysis
and EFA showed complementary results. Only the urin-
ary domain and sexual function subscale reached the
goal of good construct validity. Most of the dimensions
showed good discriminant validity, except for bowel and
hormonal functions. The bowel bother subscale also ex-
hibited good convergent validity. The sexual function
and bother subscales seemed to capture complementary
results, since a bidimensional component was
highlighted by the EFA. In fact, these subscales were
highly correlated with two separate factors in the EFA.
Moreover, items of the sexual bother subscale were
poorly correlated to the sexual summary scores, as
shown by the multitrait analysis. The hormonal domain
presented poor construct validity overall, since neither
convergent nor discriminant validity was respected, and
correlation was observed with three of the four factors
of the EFA. These poor results for the hormonal domain
could be partially explained by the low number of pa-
tients treated by hormone therapy (only 45 patients
(20.9%)). The construct validity was not reported for the
original English version of the EPIC questionnaire, ren-
dering comparison impossible. These poor results could
also be partially explained by the low number of patients
with complete data included in the EFA analysis (only 111
patients), whereas at least 150 patients are required to en-
sure the robustness of these analyses [18]. Indeed, the
main limitation of this study is the low number of patients
involved in step 2. Only 215 patients were actually en-
rolled in step 2, whereas a sample size of 300 patients was
initially expected. Nonetheless, this sample size may be
sufficient for most of the statistical analyses, even though
the observed statistical power was lower than expected.
The low sample size stems from the fact that the inclusion
period was longer than planned, and the study had to be
interrupted due to financial constraints.
Table 5 Exploratory factor analysis with varimax rotation and 4
factors performed at the first measurement time including all
patients with complete data (N = 111)
Domain Subscale Item Factor 1 Factor 2 Factor 3 Factor 4
Urinary Function q23 0.164 −0.141 −0.676 −0.058
q24 −0.017 −0.036 0.097 −0.294
q25 0.022 0.075 −0.117 −0.583
q26 0.180 −0.024 −0.709 −0.159
q27 −0.172 0.065 0.700 0.022
Bother q28 −0.128 0.048 0.836 −0.004
q29 0.013 0.051 0.129 0.690
q30 0.142 0.098 0.129 0.245
q31 −0.009 0.135 0.502 0.323
q32 −0.091 0.237 0.467 0.351
q33 −0.182 0.149 0.505 0.176
q34 −0.121 0.206 0.617 0.304
Bowel Function q42 0.167 0.059 0.001 −0.304
q43 −0.064 −0.232 −0.410 −0.064
q44 −0.114 0.114 0.151 0.265
q45 −0.144 0.005 0.240 −0.055
q46 −0.191 0.096 −0.038 0.398
q47 −0.149 −0.025 −0.041 0.277
q48 −0.063 0.056 −0.185 −0.586
Bother q49 −0.175 0.164 0.148 0.579
q50 −0.129 0.107 0.264 0.557
q51 0.008 0.216 −0.017 0.504
q52 0.145 0.192 0.234 0.483
q53 0.021 0.184 0.076 0.384
q54 0.098 0.066 −0.028 0.765
q55 −0.078 0.326 0.058 0.384
Sexual Function q56 0.820 0.097 −0.056 0.007
q57 0.909 −0.101 −0.056 0.024
q58 0.885 0.002 −0.077 0.005
q59 0.846 0.008 −0.127 0.012
q60 0.884 −0.093 −0.060 0.005
q61 0.604 0.037 −0.143 −0.065
q62 0.791 0.092 −0.099 −0.027
q63 0.838 0.134 −0.053 −0.005
q64 0.923 −0.041 0.037 −0.074
Bother q65 0.022 0.831 0.099 −0.013
q66 −0.013 0.838 0.045 0.029
q67 0.017 0.841 0.058 0.007
q68 −0.047 0.735 0.067 0.041
Hormonal Function q69 0.260 −0.087 −0.239 0.032
q70 −0.104 0.056 −0.412 0.151
q71 −0.052 −0.646 0.024 −0.074
Table 5 Exploratory factor analysis with varimax rotation and 4
factors performed at the first measurement time including all
patients with complete data (N = 111) (Continued)
q72 0.071 −0.564 −0.179 −0.065
q73 0.074 −0.034 0.249 0.060
Bother q74 −0.157 0.279 0.270 −0.101
q75 0.131 −0.046 0.443 −0.119
q76 0.212 0.057 0.054 0.141
q77 0.112 0.662 0.020 0.256
q78 −0.018 0.636 0.161 0.137
q79 −0.019 0.159 0.266 0.133
Values in bold correspond to the highest correlation observed between each
item and factors
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Table 6 Interscale correlations between EPIC summary scores and subscales and QLQ-PR25 scores (N = 215; T1)
EPIC Urinary Bowel Sexual Hormonal
Domain Function Bother Irritation Obstruction Incontinence Domain Function Bother Domain Function Bother Domain Function Bother
QLQ-PR25
Sexual activity −0.13 −0.13 −0.12 −0.12 −0.10 −0.09 −0.15 −0.07 −0.48 −0.65 0.17 −0.08 −0.15 −0.05
Sexual functioning −0.21 −0.20 −0.20 −0.16 −0.23 −0.25 −0.16 −0.25 −0.62 −0.62 −0.20 −0.15 −0.23 −0.14
Urinary symptoms −0.83 −0.62 −0.81 −0.76 −0.59 −0.58 −0.51 −0.48 −0.32 −0.31 −0.06 −0.38 −0.40 −0.34
Bowel symptoms −0.44 −0.45 −0.39 −0.34 −0.41 −0.65 −0.54 −0.62 −0.28 −0.23 −0.12 −0.36 −0.28 −0.35
Hormonal treatment-related symptoms −0.33 −0.23 −0.37 −0.30 −0.24 −0.33 −0.34 −0.27 −0.40 −0.36 −0.17 −0.52 −0.45 −0.50
Incontinence aid −0.66 −0.61 −0.60 −0.30 −0.65 −0.27 −0.38 −0.10 −0.55 −0.43 −0.53 −0.57 −0.58 −0.40
Values in bold correspond to correlation between EPIC domains and subscales and the equivalents scales of the QLQ-PR25. For the QLQ-PR25 a high score indicates a high functional level and a high symptomatic



















One of the strengths of this study is the assessment of
all psychometric properties, including both reproducibility
and sensitivity to change, which are not always systematic-
ally assessed in the validation process of HRQoL question-
naires. In order to complement these results according to
classical test theory, particularly the construct validity, a
modern psychometric approach using item response the-
ory is essential [27], such as the use of Rasch-family
models [28, 29]. These analyses are planned and will be
fully reported in a separate paper. Moreover, these ana-
lyses present the advantage of being robust in the pres-
ence of missing data, and thus, all patients with at least
one item completed can contribute to the analyses [30].
These further analyses should make it possible to validate
or rule out the trend observed on EFA analysis.
It would also be interesting to study the impact of
other demographic and clinical data on the results of the
EPIC validation, including the impact of age, relationship
status or treatment modality and race. However, the
sample size was not sufficient to ensure adequate vari-
ability to enable these additional analyses. We also plan
to study the occurrence of differential item functioning
using item response theory analysis. While the impact of
race could be of interest, in France, as in several other
European countries, current legislation does not allow
data on racial origin to be collected routinely in studies,
without ample justification of the importance of this
variable.
Another strength of this study is that both patients
with ongoing treatment and cured patients were in-
cluded in the validation process. This enables validation
of the EPIC questionnaire for future epidemiological
studies performed late after diagnosis.
This adaptation and validation of the French version
of the EPIC questionnaire was essential in order to en-
able the use this tool in future French-language studies.
This validation was also mandatory to enable the second
part of the QALIPRO study, which aims to investigate
the long-term side effects of prostate cancer treatment.
Moreover, although this questionnaire was initially de-
veloped for prostate cancer patients, other elderly pa-
tients without prostate cancer could be concerned by
some of the issues mentioned in this instrument. In fact,
in the debriefing questionnaire in step 1, forty-one pa-
tients (91.1%) considered that the questionnaire could
concern other men with no prostate cancer.
Table 7 Mean difference between the two assessments (T2 minus T1) for Treatment group patients, comparing patients without
toxicities with patients who experienced toxicities during treatment, in order to assess sensitivity to change
Patients without toxicities (N = 70) Patients experienced toxicities (N = 55)
Dimensions N mean difference (SD) SRM N mean difference (SD) SRM P-value
HRQoL domain summary scores
Urinary 41 −18.49 (22.80) −0.81 43 −27.64 (19.44) −1.42 0.051
Bowel 40 −11.30 (17.15) −0.66 39 −9.16 (12.16) −0.75 0.522
Sexual 48 −13.61 (17.72) −0.77 44 −30.59 (24.42) −1.25 <0.001
Hormonal 36 −6.48 (13.67) −0.47 41 −5.29 (10.24) −0.52 0.664
Domain-specific HRQoL subscales
Urinary subscales
Function 52 −18.48 (22.57) −0.82 47 −31.57 (21.21) −1.49 0.004
Bother 39 −20.25 (24.54) −0.83 41 −24.03 (24.01) −1.00 0.489
Irritation/obstruction 40 −16.96 (23.39) −0.73 41 −15.90 (21.00) −0.76 0.830
Incontinence 41 −18.13 (29.86) −0.61 43 −45.67 (31.66) −1.44 <0.001
Bowel subscales
Function 51 −11.03 (17.15) −0.64 48 −10.79 (15.21) −0.71 0.941
Bother 39 −9.20 (17.01) −0.54 39 −6.01 (15.49) −0.39 0.389
Sexual subscales
Function 47 −21.80 (23.42) −0.93 44 −38.68 (24.32) −1.59 0.001
Bother 41 1.83 (24.34) 0.07 43 −14.10 (37.05) −0.38 0.022
Hormonal subscales
Function 49 −5.13 (14.10) −0.36 46 −7.42 (15.61) −0.47 0.454
Bother 38 −6.64 (14.89) −0.45 41 −4.27 (10.75) −0.40 0.422
SD standard deviation, SRM standardized Response Mean; P-value of paired T-test
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Conclusions
In conclusion, the French version of the EPIC question-
naire showed good psychometric properties in patients
with prostate cancer, similar to those of the original Eng-
lish version. An item response theory analysis will
complete these results.
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